Inhibition of ovarian cancer cell-derived TGF-β2 in xenograft models reduced the number of αSMA+ stromal cells in omental implants by 90% and the tumor mitotic activity by 75% (46). This evidence concerns the gene ACTA1 and ovarian carcinoma.